Description
Pralsetinib is a selective RET kinase inhibitor approved for treating certain types of cancer with RET gene alterations. However, it is not currently approved specifically for colorectal cancer treatment.
Mechanism of Action
Pralsetinib works by selectively inhibiting RET (rearranged during transfection) kinase activity, blocking abnormal cell growth signals in tumors with RET gene fusions or mutations.
Side Effects
Fatigue
Constipation
Hypertension
Musculoskeletal pain
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT05525858
Not Applicable
Recruiting
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
South Korea
NCT03037385
Phase 1
Archived
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
United States, Belgium, China, France, Germany, Hong Kong, Italy, Netherlands, S
Quick Info
| Brand Name | Gavreto |
| Category | Targeted Therapy |
 EMA Status | Not submitted to EMA |
 Spain Access | Not available |
| Clinical Trials | 2 |
Related Medications
Regorafenib
Targeted Therapy
107 trials
Rego
Targeted Therapy
107 trials
Fruquintinib
Targeted Therapy
57 trials
Encorafenib
Targeted Therapy
26 trials
Binimetinib
Targeted Therapy
22 trials
Trametinib
Targeted Therapy
22 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.